title: Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression.
abstract: Histone deacetylase (HDAC) activity plays the role of deacetylation of histone and non-histone proteins, which can alter gene expression patterns and cell behavior potentially associated with malignant transformation. Aberrant expression of HDAC1 has been found in various types of cancers, which indicated that it might be a target for cancer therapy. In this study, overexpression of HDAC1 was found in esophageal cancer samples by real-time RT-PCR, compared with adjacent non-cancerous tissues. To further verify the possibility of anticancer treatment by silencing the increased HDAC1 in esophageal carcinoma cells, HDAC1 expression was knockdown using plasmid-based RNA interference (RNAi). Results showed the HDAC1 expression was efficiently inhibited and the acetylation of histone H3 was significantly increased by RNAi in EC109 cells. Increased apoptotic cell death was observed when HDAC1 expression was knockdown, which indicated that cells were more sensitive to radiation. Moreover, the results also showed DNA was more easily broken by radiation in EC109 cells when HDAC1 expression was knockdown, as measured by γH2AX foci and single-cell electrophoresis. Our data suggested that targeting the increased HDAC1 expression might be feasible for esophageal cancer therapy.
authors.affiliation: Department of Medical Genetics, College of Basic Medicine, Third Military Medical University, 400038 Chongqing, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Zhang
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Xueli
authors.initials: X
authors.lastname: Pang
mesh_terms: D017209:Apoptosis / Q000235:genetics / Q000528:radiation effects; D015153:Blotting, Western; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000528:radiation effects; D020552:Comet Assay; D004938:Esophageal Neoplasms / Q000235:genetics* / Q000378:metabolism; D005455:Fluorescent Antibody Technique; D055785:Gene Knockdown Techniques / Q000379:methods; D056284:Histone Deacetylase 1 / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D034622:RNA Interference; D011836:Radiation Tolerance / Q000235:genetics*; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection
chemical_list: C110550:HDAC1 protein, human; D056284:Histone Deacetylase 1
references.citation: Oncogene. 2007 Jun 7;26(27):3963-71
references.pmid: 17213813
references.citation: Cell Cycle. 2004 May;3(5):534-5
references.pmid: 15020838
references.citation: Mutat Res. 1992 Jun;271(3):243-52
references.pmid: 1378197
references.citation: Nat Rev Drug Discov. 2006 Sep;5(9):769-84
references.pmid: 16955068
references.citation: Cancer Biol Ther. 2009 May;8(9):823-31
references.pmid: 19270532
references.citation: Int J Cancer. 2010 Mar 1;126(5):1246-55
references.pmid: 19676051
references.citation: Lancet Oncol. 2008 Feb;9(2):139-48
references.pmid: 18207460
references.citation: Biochem Biophys Res Commun. 2003 Oct 17;310(2):529-36
references.pmid: 14521942
references.citation: Biotechnol J. 2009 Mar;4(3):375-90
references.pmid: 19296442
references.citation: Histopathology. 2009 May;54(6):688-98
references.pmid: 19438744
references.citation: Cancer Res. 2006 Dec 1;66(23):11298-304
references.pmid: 17145876
references.citation: Breast Cancer Res Treat. 2005 Nov;94(1):11-6
references.pmid: 16172792
references.citation: BJU Int. 2010 Apr;105(8):1181-6
references.pmid: 19681894
references.citation: Oncogene. 2009 Apr 9;28(14):1714-24
references.pmid: 19252524
references.citation: J Biol Chem. 2005 Jul 22;280(29):26729-34
references.pmid: 15937340
references.citation: Mol Cell Biol. 2007 Jul;27(13):4784-95
references.pmid: 17470557
references.citation: Cancer Gene Ther. 2009 Aug;16(8):609-19
references.pmid: 19444302
references.citation: Cancer Gene Ther. 2010 Feb;17(2):120-30
references.pmid: 19730451
references.citation: Histopathology. 2008 Sep;53(3):267-77
references.pmid: 18671804
references.citation: Mol Cancer Ther. 2006 Aug;5(8):1967-74
references.pmid: 16928817
references.citation: Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):87-92
references.pmid: 11134513
references.citation: Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9
references.pmid: 10954755
references.citation: Nat Biotechnol. 2002 May;20(5):505-8
references.pmid: 11981566
references.citation: Radiat Oncol. 2006 Aug 03;1:25
references.pmid: 16887021
references.citation: Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):534-42
references.pmid: 19735878
references.citation: Clin Cancer Res. 2009 Sep 1;15(17):5396-403
references.pmid: 19706820
references.citation: Oncol Rep. 2003 Mar-Apr;10(2):333-8
references.pmid: 12579268
references.citation: Lung Cancer. 2004 Nov;46(2):171-8
references.pmid: 15474665
references.citation: J Biol Chem. 1998 Mar 6;273(10):5858-68
references.pmid: 9488723
references.citation: Science. 1975 Nov 28;190(4217):893-4
references.pmid: 1059262
references.citation: Oncogene. 2007 Aug 13;26(37):5528-40
references.pmid: 17694092
references.citation: J Gynecol Oncol. 2008 Sep;19(3):185-90
references.pmid: 19471575